Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (May 2023)
29 slides from Adalta's investor presentation, May 3, 2023
Slide 1: ASX Announcement: Adalta Investor Presentation Rights Offer Webinar
3 May 2023 ASX Announcement ADALTA INVESTOR PRESENTATION: RIGHTS OFFER WEBINAR MELBOURNE Australia, 3 May 2023: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform, announced the launch of a non-renounceable rights offer
Slide 2: Notes to Editors: About AdAlta
Notes to Editors About AdAlta AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody p
Slide 3: Next generation protein and cell therapies: going where antibodies cannot
For personal use only Next generation protein and cell therapies: going where antibodies cannot Tim Oldham PhD, CEO and Managing Director, AdAlta (ASX:1AD) Investor presentation, 3 May 2023
Slide 4: AdAlta business and focus
Investor presentation – May 2023 2 AdAlta business and focus For personal use only Purpose: to go where antibodies cannot High-value therapeutic product pipeline in areas where traditional antibodies are ineffective Discovery business Product development business Fibrosis/inflammation pipeline Immun
Slide 5: AdAlta's customer value proposition: high value therapeutics addressing difficult targets
Investor presentation – May 2023 3 AdAlta’s customer value proposition: high value therapeutics addressing difficult targets for challenging diseases For personal use only Fibrosis: degenerative, progressive, fatal AdAlta’s AD-214 could meet a desperate need for new approaches for debilitating disea
Slide 6: May 2023 Rights Offer details
Investor presentation – May 2023 4 May 2023 Rights Offer details* For personal use only Use of funds Allocation of Offer The Offer funds (A$ million) Recommence clinical development of To raise (before exercise of any options) 1.36 AD-214 approximately A$3.15m Continue existing partnering 0.41 discu
Slide 7: AD-214 program
For personal use only AD-214 program 5
Slide 8: The need: Idiopathic Pulmonary Fibrosis (IPF)
Investor presentation – May 2023 9 The need: Idiopathic Pulmonary Fibrosis (IPF) For personal use only Scarring of the lungs irreversibly reduces lung function >300,000 people living with IPF; 40,000 people die every year 3.8 years median survival Two current therapies sell for $4.7b per year … … de
Slide 9: AD-214: efficacy validated in IPF mouse model; safety and target engagement in Phase I
Investor presentation – May 2023 7 AD-214: efficacy validated in IPF mouse model; safety and target engagement in Phase I For personal use only AD-214 inhibited development of lung fibrosis in a mouse AD-214 was well tolerated in Phase I clinical trials and model at a wide range of doses and dose in
Slide 10: Active partnering discussions ongoing while AdAlta prepares AD-214 for Phase II
Investor presentation – May 2023 8 Active partnering discussions ongoing while AdAlta prepares AD-214 for Phase II For personal use only Compelling preclinical data in hand or emerging showing Next steps AD-214 improves outcomes in four key indications Planning and preparing for Phase II IV clinical
Slide 11: Phase I extension study rationale
Investor presentation – May 2023 9 Phase I extension study rationale Planned Phase I extension study cost-effectively generates new data to support partnering AD-214 and maintain momentum to Phase II For personal use only clinical studies Establishes safety of AD-214 at likely maximum dose to be use
Slide 12: Pharma companies continue to see value in fibrosis assets: IPF examples
Investor presentation – May 2023 10 Pharma companies continue to see value in fibrosis assets: IPF examples For personal use only Date Licensor/target Licensee/acquirer Transaction Terms Clinical Phase US$80m Upfront Aug-22 2 US$620m Milestones Nov-21 US$254m Upfront 2 (Ready) Nov-21 €320m Milestone
Slide 13: Co-developed immuno-oncology discovery programs: i-CAR-cell therapies
For personal use only Co-developed immuno-oncology discovery programs: i-CAR-cell therapies 11
Slide 14: The need: multifunctional CAR-cell therapies
Investor presentation – May 2023 12 The need: multifunctional CAR-cell therapies For personal use only Therapy involves re-engineering patient’s own immune cells so they “see” cancer as a pathogen 6 FDA-approved CAR-T therapies since 2017 … but so far only for blood cancers >$US2.6 billion earned in
Slide 15: i-bodies enable optimized CAR constructs (i-CARs)
Investor presentation – May 2023 13 i-bodies enable optimized CAR constructs (i-CARs) For personal use only FEATURE BENEFIT SUPERIOR i-CAR PRODUCTS Increased CAR gene cassette/vector § CARs against novel tumor antigens Small Size capacity, efficient multi-functional CAR cell creation § Dual and bi-s
Slide 16: i-CAR-T assets: Carina co-development collaboration status
Investor presentation – May 2023 14 i-CAR-T assets: Carina co-development collaboration status For personal use only AdAlta and Carina are combining i-bodies and a world class CAR-T platform to create i-CAR-Ts that could offer improved precision, performance and persistence i-body enabled CAR-T (i-C
Slide 17: i-CAR-T: Valuable cell therapy partnering potential at pre-clinical proof of concept
Investor presentation – May 2023 15 i-CAR-T: Valuable cell therapy partnering potential at pre-clinical proof of concept For personal use only No. of Upfront payment Deal Value Upfront/target Deal value/target Date Licensee Licensor assets (US$m) (US$m) (US$m) (US$m) Jun-22 2 60 1460 30 730 Jul-20 1
Slide 18: Co-developed immuno-oncology discovery programs: i-PET imaging
For personal use only Co-developed immuno-oncology discovery programs: i-PET imaging 16
Slide 19: The need: Immuno-oncology (I/O) imaging
Investor presentation – May 2023 17 The need: Immuno-oncology (I/O) imaging For personal use only Immuno-oncology (I/O) drug market is worth US$95 billion1 … … but only 20-40% of patients respond2 to therapy Granzyme B (GZMB) is produced by immune cells to kill cancer: potential biomarker of I/O dru
Slide 20: GZMB i-PET imaging asset: GE Healthcare co-development collaboration status
Investor presentation – May 2023 18 GZMB i-PET imaging asset: GE Healthcare co-development collaboration status For personal use only AdAlta and GE are co-developing a GZMB i-body PET imaging (i-PET) asset to evaluate the effectiveness of immuno-oncology drugs ü Panel of GZMB specific i-bodies ident
Slide 21: Powerful discovery platform: i-bodies
For personal use only Powerful discovery platform: i-bodies
Slide 22: i-bodies allow for high affinity, high specificity binding to intractable targets
Investor presentation – May 2023 20 i-bodies allow for high affinity, high specificity binding to targets that are intractable for traditional antibodies For personal use only Small Antibodies i-bodies™ Flexible, modular formats Molecules Current pipeline focus CAR cell therapy ADC/ radiotherapeutic
Slide 23: AdAlta's pipeline … so far
Investor presentation – May 2023 21 AdAlta’s pipeline … so far For personal use only Discovery Non-clinical Clinical Indication Target Product Partner (route) Lead IND Discovery Preclinical Phase I Phase II optimisation enabling Lung fibrosis Available (IV/inhaled) to license Available AD-214 Kidney
Slide 24: The investment opportunity
For personal use only The investment opportunity 22
Slide 25: Strategy and upcoming CY2023 milestones to create and crystallise value
Investor presentation – May 2023 23 Strategy and upcoming CY2023 milestones to create and crystallise value For personal use only Strategy Milestone Impact • Preclinical data (Q1-H2 23) Ongoing, strengthens partnering package at low cost Realise • HREC approval, 1st patient Phase I extension (Q3 23)
Slide 26: Corporate snapshot
Investor presentation – May 2023 24 Corporate snapshot For personal use only Key financial details (28 Apr 2023) Share price performance (ASX:1AD) (last 12 months) HQ and operations Melbourne, Australia Market capitalisation A$12.91m Share price (12 month closing range) A$0.026 ($0.026 - 0.069) 12 m
Slide 27: Experienced, in-house team to execute from discovery through product development
Investor presentation – May 2023 25 Experienced, in-house team to execute from discovery through product development BOARD EXECUTIVE SCIENTIFIC ADVISORY BOARD For personal use only Paul MacLeman Patrick James, PhD Mick Foley, PhD CHAIR DIRECTOR, PLATFORM FOUNDING CHIEF AND PRODUCT SCIENTIST DISCOVER
Slide 28: Investment proposition
Investor presentation – May 2023 26 Investment proposition For personal use only Fibrosis/inflammation Immuno-oncology i-body platform to create value AD-214: Phase II and partnering 2 co-development collaborations (4 programs) Delivering high value therapeutic candidates >$4.7b market potential in
Slide 29: Contact
For personal use only Contact: Tim Oldham, CEO and Managing Director [email protected] www.adalta.com.au